Evaluation of Some Immunological Markers in the Rheumatoid Arthritis Patients

Ihsan A. Chiad1*, Hanaa S. Yossef, Muntadher A. Al-Saidi2, Mohammed A. Abbas3

1Department of Biology, College of Science, University of Baghdad, Baghdad, Iraq.
2Department of Mirobiology, College of Medicine, University of Wasit, Wasit, Iraq
3Al-Yarmouk teaching hospital, Baghdad, Iraq.

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory polyarthritic disease associated with remissions and exacerbations and characteristic genetic, clinical, pathological, and immunological features. The present study was designed to evaluate some immunological parameters of some Iraqi patients with RA. The study was carried out on 75 Iraqi RA patients who were referred to the consultant and which divided into 59 female and 16 male, treated and non-treated. The diagnosis of those patients has been performed under supervision of a specialist physician in rheumatology. Enzyme linked immunosorbent assay (ELISA) technique has been applied for the detection of anti-cyclic citrullinated peptide antibodies (anti-CCP) and (Interleukin-1α (IL-1α). The study revealed that the mean age for RA patients was (46.16±1.24) years with age range (20-67) years. The results of (anti-CCP) antibody showed significant increase in non-treated patients 86.67% (P<0.01) than Methotrexate (MTX) 70.0%, Etanercept (ETN) 53.33% treatment, also in MTX treated patients was significant increased than in ETN treatment while the mean of (IL-1α) was significant increase in non-treated patients 24.57±3.73 pg/ml than in MTX treated patients 13.54±1.16 pg/ml, ETN treated patients 13.06±0.83 pg/ml and healthy control 13.69±1.61 pg/ml.

Keywords: Rheumatoid arthritis, cytokines, anti-ccp enzyme linked immunosorbent assay.
Introduction

Rheumatoid arthritis (RA) is a chronic, systemic disease characterized by inflammation and cellular proliferation in the synovial lining of joints that can ultimately result in cartilage and bone destruction [1]. (RA) is an autoimmune disease of unknown cause. The immune system normally protects the body against foreign cells such as a virus or bacteria and can differentiate these from “self” tissues. In RA the synovium, a thin membrane that lines the joints, is seen as foreign and attacked by the immune system causing swelling, tissue damage and pain [2].

Anti-citrullinated protein antibodies (ACPA) are directed against one or more of an individual’s own, post translationally modified proteins, and frequently detected in the blood of RA patients. Anti-CGP assays are the most widely used methods to study ACPA. Anti-CGP have been evaluated in patients with early synovitis, and were found to be more specific than RF for early RA, while having comparable sensitivity [3]. Interestingly, RF and anti-CGP have both been found in blood samples taken several years before disease onset in a subset of patients [4, 5].

Several studies in recent years were conducted for evaluation of inflammatory cytokines such as IL-1α and TNF-α in rheumatoidarthritis disorders including rheumatoid arthritis to find new treatment methods base to pathogenesis. These studies reveal disequilibrium between stimulatory and inhibitory mechanisms in inflammatory disorders such as rheumatoid arthritis and cytokines (IL-1α and TNF-α) have a leading role in pathogenesis [6,7]. The cytokine level in patients with RA may be a novel approach for treatment of these disease [8]. They described successful treatment of refractory arthritis in patients with RA by infusion of antibodies against tumor necrosis factor – alpha (TNF-α), suggesting a key role for this cytokine in the pathogenesis of chronic arthritis [9].

Methotrexate (MTX) is an anchor drug for the treatment of RA because of its efficacy, acceptable safety, and cost . MTX is used in mono therapy or in combination with either biological agents or other small molecule anti-rheumatic drug [9]. Etanercept (ETN) is a soluble TNFα inhibitor and is efficiently used for the treatment of polyarticular RA [10, 11]. TNFα is a pleiotropic proinflammatory cytokine secreted by different cell types and has effects on both innate and adaptive immune cells [12].

Materials and methods

The study was carried out on 75 Iraqi RA patients who were referred to the consultant clinic at the department of Rheumatology, AL-Yarmouk teaching hospital, Baghdad teaching hospital from Dec. 2013 to May 2014. The diagnosis of those patients has been performed under supervision of a specialist physician in rheumatology department. A number of 75 Iraqi RA patients, who fulfilled the criteria for diagno

دisease. The patients age who involved in this study ranged from 20-67 years wasdivided into three groups 30 patients was gave Methotrexate(MTX) and 30 patients gave Etanercept (ETN), 15 patients without treatment for RA and 15 healthy persons acontrolgroup. From each participating subject, 3-5 ml of blood was obtained by venipuncture. The collected blood was transferred to a plain tube and left to clot at room temperature (20-25°C) for 15 minutes. The clotted blood was centrifuged at 2000 rpm for 15 minutes; and by then, serum was collected and distributed into aliquots of (200 μl) in Eppendorf tubes, which were frozen at
-20°C until laboratory assessments. Serum samples were collected from all study individuals to determine the seropositivity levels of certain cytokine:IL1- α and anti-CCP using enzyme linked immunosorbent assay (ELISA) and laboratory IL1-α kits used by Boster-USA Company(IL1-α) and Medipan-Germany (anti-CCP).

![Standard Curve of IL-1α Serum Level](image)

**Figure 1-** Standard Curve of IL-1α Serum Level.

**Statistical Analysis**

The Statistical Analysis System was used to detect the effect of different factors in study parameters. Chi-square test was used to significant comparing between percentage & least significant difference –LSD test was used to significant comparing between means in this study [13].

**Results and Discussion**

**Demographical Distribution**

The demographical distributions of the studied groups according to the age were shown in table-1. The results clarified that the age was ranged between (20 – 67 years) and the mean± SE for RA was 46.16 ± 1.24.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Mean</th>
<th>SE</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>HC</td>
<td>46.33</td>
<td>3.04</td>
<td>23.00-63.00</td>
</tr>
<tr>
<td>RA</td>
<td>46.16</td>
<td>1.24</td>
<td>20.00-67.00</td>
</tr>
</tbody>
</table>

RA= rheumatoid arthritis, HC= healthy control, SE= standard error.

The current study revealed that the age range for the majority of RA patients was at (41–60 years), which is confirmed by [14, 15]. The disease of RA can occur at any age, and its prevalence increases with age [16].

**Anti-CCP antibodies**

The results in table-2 observe a significant increase the mean of anti-ccp positivity in group III non treatment patients (86.67%) when compare with control group (P<0.01). The mean of anti-ccp positivity also showed a significant increase in group III non treatment patients comparing a group II
ETN with treated patients (53.33%) and group I MTX treated patients (70%). Also the mean of anti-ccp is significant increase in group I than in group II (P<0.01). Whereas the comparison revealed between positive and negative was appeared significant variation in positive than negative in all groups of the study except group II.

**Table 2:** Distribution Anti-CCP level in the sera of studied group.

<table>
<thead>
<tr>
<th>Groups</th>
<th>No. (%)</th>
<th>Negative</th>
<th>Positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>15 (100%)</td>
<td>0 (0.00%)</td>
<td>0 (0.00%)</td>
</tr>
<tr>
<td>I: MTX</td>
<td>9 (30.00%)</td>
<td>21 (70.00%)</td>
<td>21 (70.00%)</td>
</tr>
<tr>
<td>II: ETN</td>
<td>14 (46.67%)</td>
<td>16 (53.33%)</td>
<td>16 (53.33%)</td>
</tr>
<tr>
<td>III: Non</td>
<td>2 (13.33%)</td>
<td>13 (86.67%)</td>
<td>13 (86.67%)</td>
</tr>
</tbody>
</table>

| Chi-square (χ²) | 15.22 ** | 15.22 ** |

** ** (P<0.01).

Anti-CCP: Anti-cyclic citrullinated peptide.

Anti-CCP serological marker for RA should be highly specific for the disease and be able to distinguish RA from other arthritis that mimic RA. Recently a highly specific autoantibody system described for RA, in which patients developed. Autoantibodies to citrullinated and this has resulted in the development of anti-cyclic citrullinated peptide (anti-ccp) antibody test [17].

Our results were agreement with [15] which was observed significant increase of anti-ccp in the sera of RA patients. Also the results is agreed with [14]. Observe significantly Sakyi [19], increase of anti-ccp in the sera of RA patients.

A study has appeared the level of anti-ccp was significantly decreased in etanercept treated patients, also in our study the anti-ccp level was significant decrease when comparison with non-treatment patients Chen et al. [18].

**Interleukin- 1α: Figure-1**

The results in table - 3 appear that the mean of IL-1α is significant increase in group III non treatment (24.57 ± 3.73 pg/ml) than control (13.69 ± 1.61 pg/ml) and group I (13.54 ± 1.16 pg/ml) and group II (13.06 ± 0.83 pg/ml). While non-significant difference between control, group I and group II.

**Table 3:** The level of in IL-1α in the sera of study groups (Mean ± SE).

<table>
<thead>
<tr>
<th>Groups</th>
<th>No.</th>
<th>Mean ± SE (pg/ml) of IL-1α</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>15</td>
<td>13.69 ± 1.61 b</td>
</tr>
<tr>
<td>I: MTX</td>
<td>30</td>
<td>13.54 ± 1.16 b</td>
</tr>
<tr>
<td>II: ETN</td>
<td>30</td>
<td>13.06 ± 0.83 b</td>
</tr>
<tr>
<td>III: Non</td>
<td>15</td>
<td>24.57 ± 3.73 a</td>
</tr>
</tbody>
</table>

| LSD value | 4.918 ** |
| P-value    | 0.0001   |

** ** (P<0.01).

In the present study, the level of serum IL-1α was significantly different among RA cases and control. Elevated levels of IL-1α were not commonly found in the circulation or in body fluids except during severe disease, in which case the cytokine may be released from dying cells. It is less easy to get an impression of the role of IL-1α in the pathogenesis of inflammatory disease [20, 21]. Several studies in recent years were conducted for evaluation of inflammatory cytokines such as IL-1α and
TNF-α in rheumatologic disorders including rheumatoid arthritis to find new treatment methods base to pathogenesis. These studies reveal disequilibrium between stimulatory and inhibitory mechanisms inflammatory disorder such as rheumatoid arthritis and cytokines (IL-1α and TNF-α) have a leading role in pathogenesis [6, 7]. The result is agreement with [22] who mentioned decreased the level of IL-1α in treated RA patients by MTX. These finding demonstrate that IL-1α may have a significant effect in the pathogenesis of RA and may be used as indicators of disease activity, and MTX seems to be an efficient inhibitor of cytokine production [23 - 25]. Also [26] demonstrate increased level of IL-1α in RA patients compared with control.

References

2492


